PT1562571E - Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica - Google Patents

Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica Download PDF

Info

Publication number
PT1562571E
PT1562571E PT03783737T PT03783737T PT1562571E PT 1562571 E PT1562571 E PT 1562571E PT 03783737 T PT03783737 T PT 03783737T PT 03783737 T PT03783737 T PT 03783737T PT 1562571 E PT1562571 E PT 1562571E
Authority
PT
Portugal
Prior art keywords
immunosuppressive agent
compound
rapamycin
tissue
use according
Prior art date
Application number
PT03783737T
Other languages
English (en)
Portuguese (pt)
Inventor
John M Williams
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT1562571E publication Critical patent/PT1562571E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
PT03783737T 2002-11-21 2003-11-21 Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica PT1562571E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42832802P 2002-11-21 2002-11-21

Publications (1)

Publication Number Publication Date
PT1562571E true PT1562571E (pt) 2011-11-25

Family

ID=32393383

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03783737T PT1562571E (pt) 2002-11-21 2003-11-21 Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica

Country Status (9)

Country Link
US (3) US7217718B2 (https=)
EP (1) EP1562571B1 (https=)
JP (2) JP4914008B2 (https=)
AT (1) ATE520400T1 (https=)
AU (1) AU2003291143A1 (https=)
DK (1) DK1562571T3 (https=)
ES (1) ES2371635T3 (https=)
PT (1) PT1562571E (https=)
WO (1) WO2004047826A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100494182C (zh) 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
WO2013142376A1 (en) * 2012-03-19 2013-09-26 Aposignal Bioscience Llc Composition and methods for cell modulation
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
KR102490952B1 (ko) * 2016-05-03 2023-01-19 에스큐지 바이오테크놀로지스 컴퍼니 관용을 유도하는 생체분자의 세포내 전달

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB401747A (en) * 1932-12-28 1933-11-23 Charles Hepburn Myrtle Method of and means for disinfecting air and distributing the treated air
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) * 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5861382A (en) * 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU5152293A (en) 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
JPH11501289A (ja) * 1994-12-02 1999-02-02 藤沢薬品工業株式会社 Ｎｏ介在疾患の予防および／または治療のためのペプチド化合物
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
ATE259235T1 (de) * 1995-07-20 2004-02-15 Cell Eng Ag Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
IL115245A (en) * 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
WO1997019075A1 (en) * 1995-11-22 1997-05-29 Darwin Discovery Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
JP2001513754A (ja) * 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998039026A2 (en) * 1997-03-07 1998-09-11 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6359061B1 (en) * 1999-03-19 2002-03-19 Isis Pharmaceuticals, Inc. Amide compound libraries
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
CN100494182C (zh) * 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
AU2001260081B2 (en) * 2000-05-22 2005-07-28 Leo Pharma A/S Benzophenones as inhibitors of il-1beta and tnf-alpha
AU2003280429A1 (en) * 2002-06-26 2004-01-19 The Trustees Of Columbia Uninersity In The City Of New York Use of streptavidin to inhibit transplant rejection
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents

Also Published As

Publication number Publication date
ATE520400T1 (de) 2011-09-15
JP2011016851A (ja) 2011-01-27
US20100233158A1 (en) 2010-09-16
US20070219264A1 (en) 2007-09-20
US7217718B2 (en) 2007-05-15
WO2004047826A1 (en) 2004-06-10
US20040167202A1 (en) 2004-08-26
HK1074797A1 (en) 2005-11-25
EP1562571B1 (en) 2011-08-17
DK1562571T3 (da) 2011-12-05
ES2371635T3 (es) 2012-01-05
EP1562571A1 (en) 2005-08-17
AU2003291143A1 (en) 2004-06-18
JP4914008B2 (ja) 2012-04-11
US7678822B2 (en) 2010-03-16
JP2006514015A (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
JP2547162B2 (ja) 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物
CZ288382B6 (en) Pharmaceutical preparation for treating viral infections
US7678822B2 (en) Induction of immune tolerance
US5550153A (en) Method for treating heartworm-infected canines
AU2002311601C1 (en) Non-myeloablative tolerogenic treatment with tyrphostins
WO2001024791A1 (en) Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders
US8497300B2 (en) Arsenic therapy for APLS-type autoimmune lymph-oproliferative syndrome in mice and humans
AU615745B2 (en) Method of effecting immunosuppression
WO2005004789A2 (en) Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna
TW202120092A (zh) 化合物用於預防或治療移植物抗宿主病的用途
JP4629964B2 (ja) ウシの消化器疾患治療剤
JP2006514015A5 (https=)
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
HK1074797B (en) Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
Prescott et al. Effect of glycerine on toxicity of isoniazid in mice
KR20250044649A (ko) X-ald 치료를 위한 갑상선 베타-작용제 투여 요법
Wimer Mitogens for curative therapy of HIV-1 infections; an update
Cleveland Chronic latent herpesvirus infections and their activation
JPH01207235A (ja) 癌細胞転移抑制剤
RO116162B1 (ro) Compoziţie farmaceutică şi metodă pentru tratamentul profilactic şi curativ al parvovirozei şi coronavirozei la câine
JP2010189448A (ja) ウシの消化器疾患治療剤
RU2006113234A (ru) Способ комплексной активизации деятельности защитных приспособлений организма животного